One year in review
Behçet's syndrome: one year in review 2025
G. Hatemi1, E. Seyahi2, I. Fresko3, R. Talarico4, D. Uçar5, V. Hamuryudan6
- Division of Rheumatology, Department of Internal Medicine, School of Medicine, Behçet’s Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey.
- Division of Rheumatology, Department of Internal Medicine, School of Medicine, Behçet’s Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey.
- Division of Rheumatology, Department of Internal Medicine, School of Medicine, Behçet’s Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Division of Ophthalmology, School of Medicine, Behçet’s Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey.
- Division of Rheumatology, Department of Internal Medicine, School of Medicine, Behçet’s Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey. vhamuryudan@yahoo.com
CER19240
2025 Vol.43, N°10
PI 1699, PF 1708
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 41133359 [PubMed]
Received: 25/08/2025
Accepted : 01/10/2025
In Press: 23/10/2025
Published: 23/10/2025
Abstract
Behçet’s syndrome (BS) is a variable-vessel vasculitis with multiorgan involvement and heterogeneous clinical manifestations. A list of studies were published on BS last year including studies that explore the epidemiology of BS in different parts of the world, role of potential immunological biomarkers in major organ involvement phenotypes, genome wide association studies, studies on micro RNAs, toll like receptors, neutrophil function and epigenetics that added to our understanding of the pathogenesis, studies on imaging and clinical findings that aim to improve diagnosis, differential diagnosis, and monitoring of each organ involvement, as well as studies on management, especially focusing on the role of TNF inhibitors compared to conventional immunosuppressives. The aim of this review is to provide a critical digest of the studies on BS published during 2024.
